LuMind IDSC Acknowledged by T21RS For Work on COVID-19 Survey
LuMind IDSC Foundation President/CEO Hampus Hillerstrom and Chief Scientific Officer James Hendrix acknowledged for their efforts on the T21RS COVID-19 survey. Here is an excerpt from the T21RS Newsletter: Meanwhile, […]
myDSC Webinar – Fighting Alzheimer’s Disease in Down Syndrome: There is Hope!
November 12, 2020 1PM ET | 12 PM CT | 11 AM MT | 10 AM PT Learn about the association between Alzheimer’s disease and Down syndrome, the latest advances […]
The LuMind IDSC Foundation Partners with Eli Lilly and Company to Measure Blood Biomarkers in LIFE-DSR Natural History Study
October 29, 2020 (Burlington, MA). LuMind IDSC Foundation today announced a new partnership with Eli Lilly and Company (Lilly) aimed at addressing the under-representation of adults with Down syndrome in […]
LuMind IDSC and NDSS Submit Joint Recommendations for Advancing NIH-Funded Down Syndrome Research
Boston, MA and New York, NY (July 14, 2020) – The LuMind IDSC Foundation and the National Down Syndrome Society (NDSS), the leading national Down syndrome research and advocacy organizations, submitted […]
T21RS Publishes Initial Results of COVID-19 and Down Syndrome Survey and Seeks More Participants
I recently had the pleasure of interviewing the Trisomy 21 Research Society (T21RS) COVID-19 Task Force members who launched a study to evaluate the effects of virus on children and […]
National Down Syndrome Organizations Combine Efforts to Publish Q&A on COVID-19 and Down Syndrome
PLYMOUTH, MINN., DENVER, BURLINGTON, MASS., ATLANTA, NEW YORK CITY, HAMDEN, CONN. March 27, 2020 – Today, an important Q&A on COVID-19 and Down syndrome was published by a consortium of national […]
A Memory Drug for Down Syndrome?
“We started with a situation that looked hopeless, nobody thought anything could be done. But we may have struck gold.” –Peter Walter, PhD. The cognitive features of Down syndrome (DS) […]
$60M in NIH INCLUDE Funding for Down Syndrome Research in 2020
We are excited to see an increase in funding for Down syndrome research! In December, President Trump signed a spending package which includes $60 million for Down syndrome research in […]
Clinical Trial Volunteers Give The Gift That Keeps On Giving
During the holiday season, we are all asked to donate money to causes that we care about to make the world a better place. With this in mind, it is […]
Biogen Announces New Hope for Alzheimer’s Drug Candidate Aducanumab
On October 22, 2019, the biopharmaceutical company, Biogen, announced that they will be going to the FDA to seek approval for their Alzheimer’s disease drug candidate, aducanumab. If approved, this […]